JP2008513366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513366A5 JP2008513366A5 JP2007530802A JP2007530802A JP2008513366A5 JP 2008513366 A5 JP2008513366 A5 JP 2008513366A5 JP 2007530802 A JP2007530802 A JP 2007530802A JP 2007530802 A JP2007530802 A JP 2007530802A JP 2008513366 A5 JP2008513366 A5 JP 2008513366A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- protein kinase
- dependent
- cancer
- kinase dependent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- -1 c-Abl Proteins 0.000 claims description 3
- 230000001419 dependent Effects 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 16
- 102000001253 Protein Kinases Human genes 0.000 claims 15
- 108060006633 Protein Kinases Proteins 0.000 claims 15
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 2
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 2
- 102100009831 EPHB4 Human genes 0.000 claims 2
- 101700032546 EPHB4 Proteins 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 108091007929 PDGF receptors Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 2
- 201000009925 nephrosclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002062 proliferating Effects 0.000 claims 2
- JNLSTLQFDDAULK-UHFFFAOYSA-N 6-[6-(hydroxymethyl)pyrimidin-4-yl]oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide Chemical compound C1=NC(CO)=CC(OC=2C=C3C=CC=C(C3=CC=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=N1 JNLSTLQFDDAULK-UHFFFAOYSA-N 0.000 claims 1
- 208000009956 Adenocarcinoma Diseases 0.000 claims 1
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 1
- 206010051113 Arterial restenosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010028537 Myelofibrosis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000003476 Primary Myelofibrosis Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 210000003802 Sputum Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000009273 endometriosis Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 claims 1
- 230000001631 hypertensive Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 230000001732 thrombotic Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000006542 von Hippel-Lindau Disease Diseases 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PGFQDLOMDIBAPY-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C(F)C(C(F)(F)F)=C1 PGFQDLOMDIBAPY-UHFFFAOYSA-N 0.000 description 1
- DLOAPXKILLGWHB-UHFFFAOYSA-N 6-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-propan-2-ylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]isoquinoline-1-carboxamide Chemical compound C1CN(C(C)C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=NC=CC2=CC(OC=3N=CN=C(NC(C)=O)C=3)=CC=C12 DLOAPXKILLGWHB-UHFFFAOYSA-N 0.000 description 1
- UQALKJYOYJHRRA-UHFFFAOYSA-N 6-(6-chloropyrimidin-4-yl)oxy-N-[4-fluoro-3-(trifluoromethyl)phenyl]isoquinoline-1-carboxamide Chemical group C1=C(C(F)(F)F)C(F)=CC=C1NC(=O)C1=NC=CC2=CC(OC=3N=CN=C(Cl)C=3)=CC=C12 UQALKJYOYJHRRA-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
Description
実施例108:6−(6−アセチルアミノ−ピリミジン−4−イルオキシ)−イソキノリン−1−カルボン酸[4−(4−イソプロピル−ピペラジン−1−イルメチル)−3−トリフルオロメチル−フェニル]−アミド
この化合物を実施例103と同様に、6−(6−クロロ−ピリミジン−4−イルオキシ)−イソキノリン−1−カルボン酸(4−フルオロ−3−トリフルオロメチル−フェニル)−アミドに代えて6−(6−クロロ−ピリミジン−4−イルオキシ)−イソキノリン−1−カルボン酸[4−(4−イソプロピル−ピペラジン−1−イルメチル)−3−トリフルオロメチル−フェニル]−アミドを使用して、工程103.3において4−フルオロ−3−トリフルオロメチルアニリンに代えて4(−4−イソプロピルピペラジン−1−イルメチル)−3−トリフルオロメチル−フェニルアミンを使用して、得ることができる。ベージュ色の粉末:1H-NMR(DMSO-d6): δ ppm 0.96(d, J=6.5 Hz, 6 H) 2.13(s, 3 H) 2.34 - 2.48(m, 8 H) 2.60(sept., J=6.5 Hz, 1 H) 3.56(s, 2 H) 7.62(dd, J=9.3, 2.5 Hz, 1 H) 7.68(d, J=0.9 Hz, 1 H) 7.73(d, J=8.5 Hz, 1 H) 7.93(d, J=2.5 Hz, 1 H) 8.03 - 8.13(m, 2 H) 8.35(d, J=2.1 Hz, 1 H) 8.51(d, J=1.0 Hz, 1 H) 8.63(d, J=5.6 Hz, 1 H) 8.95(d, J=9.3 Hz, 1 H) 11.02(s, 1 H) 11.12(s, 1 H)。
この化合物を実施例103と同様に、6−(6−クロロ−ピリミジン−4−イルオキシ)−イソキノリン−1−カルボン酸(4−フルオロ−3−トリフルオロメチル−フェニル)−アミドに代えて6−(6−クロロ−ピリミジン−4−イルオキシ)−イソキノリン−1−カルボン酸[4−(4−イソプロピル−ピペラジン−1−イルメチル)−3−トリフルオロメチル−フェニル]−アミドを使用して、工程103.3において4−フルオロ−3−トリフルオロメチルアニリンに代えて4(−4−イソプロピルピペラジン−1−イルメチル)−3−トリフルオロメチル−フェニルアミンを使用して、得ることができる。ベージュ色の粉末:1H-NMR(DMSO-d6): δ ppm 0.96(d, J=6.5 Hz, 6 H) 2.13(s, 3 H) 2.34 - 2.48(m, 8 H) 2.60(sept., J=6.5 Hz, 1 H) 3.56(s, 2 H) 7.62(dd, J=9.3, 2.5 Hz, 1 H) 7.68(d, J=0.9 Hz, 1 H) 7.73(d, J=8.5 Hz, 1 H) 7.93(d, J=2.5 Hz, 1 H) 8.03 - 8.13(m, 2 H) 8.35(d, J=2.1 Hz, 1 H) 8.51(d, J=1.0 Hz, 1 H) 8.63(d, J=5.6 Hz, 1 H) 8.95(d, J=9.3 Hz, 1 H) 11.02(s, 1 H) 11.12(s, 1 H)。
Claims (12)
- 6−(6−ヒドロキシメチル−ピリミジン−4−イルオキシ)−ナフタレン−1−カルボン酸(3−トリフルオロメチル−フェニル)−アミド、またはその互変異性体、あるいはその塩。
- 請求項1に記載の式Iの化合物および薬学的に許容される担体を含む医薬組成物。
- 動物またはヒトの処置に使用するための、請求項1に記載の化合物。
- プロテインキナーゼ依存性疾患の処置において使用するための、請求項3に記載の化合物。
- 処置されるプロテインキナーゼ依存性疾患が、EphB4、c−Abl、Bcr−Abl、c−Kit、Raf、RET、PDGF−RおよびVEGF−Rの1種以上のプロテインキナーゼに依存するプロテインキナーゼ依存性疾患である、請求項4に記載の化合物。
- プロテインキナーゼ依存性疾患がVEGF−Rに依存するプロテインキナーゼ依存性疾患である、請求項5に記載の化合物。
- プロテインキナーゼ依存性疾患が増殖性疾患である、請求項4から6の何れかに記載の化合物。
- プロテインキナーゼ依存性疾患の処置用医薬組成物の製造のための、請求項1に記載の化合物の使用。
- プロテインキナーゼ依存性疾患が、EphB4、c−Abl、Bcr−Abl、c−Kit、Raf、RET、PDGF−RおよびVEGF−Rの1種以上のプロテインキナーゼに依存するプロテインキナーゼ依存性疾患である、請求項8に記載の使用。
- プロテインキナーゼ依存性疾患が、VEGF−Rに依存するプロテインキナーゼ依存性疾患である、請求項9に記載の使用。
- プロテインキナーゼ依存性疾患が増殖性疾患である、請求項8から10のいずれかに記載の使用。
- プロテインキナーゼ依存性疾患が眼血管新生、糖尿病性網膜症、加齢斑変性、乾癬、フォン・ヒッペル・リンドウ病、血管芽細胞腫、血管腫、糖尿病性腎症、悪性腎硬化症、血栓性微小血管症候群、移植片拒絶、糸球体腎炎、メサンギウム増殖性糸球体腎炎、溶血性尿毒症症候群、糖尿病性腎症、高血圧性腎硬化症、粉瘤、動脈再狭窄、自己免疫疾患、急性炎症、肝硬変、糖尿病、子宮内膜症、慢性喘息、動脈または移植後アテローム性動脈硬化症、神経変性障害、白血病、乳癌、腺癌腫、結直腸がん、肺がん、腎がん、肝臓がん、膵臓がん、卵巣がん、前立腺のがん、骨髄腫、多発性骨髄腫、骨髄異形成症候群、AML(急性骨髄性白血病)、AMM(原発性骨髄線維症)、中皮腫、神経膠腫および膠芽細胞腫から選択される、請求項4から7のいずれかに記載の化合物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0420520.9 | 2004-09-15 | ||
GB0420520A GB0420520D0 (en) | 2004-09-15 | 2004-09-15 | Organic compounds |
GB0511687.6 | 2005-06-08 | ||
GB0511687A GB0511687D0 (en) | 2005-06-08 | 2005-06-08 | Organic compounds |
PCT/IB2005/004030 WO2006059234A2 (en) | 2004-09-15 | 2005-09-14 | Bicyclic amides as kinase inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011050331A Division JP2011148808A (ja) | 2004-09-15 | 2011-03-08 | キナーゼ阻害剤としての二環式アミド |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008513366A JP2008513366A (ja) | 2008-05-01 |
JP2008513366A5 true JP2008513366A5 (ja) | 2011-04-28 |
JP4950889B2 JP4950889B2 (ja) | 2012-06-13 |
Family
ID=35705284
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007530802A Expired - Fee Related JP4950889B2 (ja) | 2004-09-15 | 2005-09-14 | キナーゼ阻害剤としての二環式アミド |
JP2011050331A Pending JP2011148808A (ja) | 2004-09-15 | 2011-03-08 | キナーゼ阻害剤としての二環式アミド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011050331A Pending JP2011148808A (ja) | 2004-09-15 | 2011-03-08 | キナーゼ阻害剤としての二環式アミド |
Country Status (23)
Country | Link |
---|---|
US (2) | US8026247B2 (ja) |
EP (1) | EP1794149A2 (ja) |
JP (2) | JP4950889B2 (ja) |
KR (3) | KR20100103890A (ja) |
CN (1) | CN101693709A (ja) |
AR (1) | AR050932A1 (ja) |
AU (2) | AU2005310968C1 (ja) |
BR (1) | BRPI0515446A (ja) |
CA (2) | CA2738383A1 (ja) |
EC (1) | ECSP077324A (ja) |
GT (1) | GT200500260A (ja) |
IL (1) | IL181720A0 (ja) |
MA (1) | MA28876B1 (ja) |
MX (1) | MX2007003013A (ja) |
MY (2) | MY147640A (ja) |
NO (1) | NO20071875L (ja) |
NZ (3) | NZ587806A (ja) |
PE (1) | PE20060664A1 (ja) |
RU (3) | RU2416611C2 (ja) |
SG (1) | SG155921A1 (ja) |
TN (1) | TNSN07093A1 (ja) |
TW (1) | TW200626576A (ja) |
WO (1) | WO2006059234A2 (ja) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1667964T1 (sl) | 2003-09-19 | 2009-12-31 | Janssen Pharmaceutica Nv | 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi |
PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
MY147518A (en) | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
CN101365682A (zh) | 2005-12-08 | 2009-02-11 | 千禧药品公司 | 具有激酶抑制活性的双环化合物 |
GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
GB0605120D0 (en) * | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
EP2007391B8 (en) | 2006-04-07 | 2013-05-29 | Novartis AG | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315ile kinase inhibitor |
UY30288A1 (es) | 2006-04-18 | 2007-08-31 | Janssen Pharmaceutica Nv | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
WO2008031835A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
WO2008092199A1 (en) | 2007-01-31 | 2008-08-07 | Cytopia Research Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
JP2010524885A (ja) * | 2007-04-17 | 2010-07-22 | ノバルティス アーゲー | がん治療剤としてのナフタレンカルボン酸アミドのエーテル |
EP2150545A1 (en) * | 2007-04-27 | 2010-02-10 | AstraZeneca AB | N' - (phenyl) -n- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions |
CL2008002786A1 (es) * | 2007-09-20 | 2009-05-15 | Novartis Ag | Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion. |
CN103965200B (zh) | 2008-09-22 | 2016-06-08 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物 |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
US20110112121A1 (en) | 2009-07-06 | 2011-05-12 | Joerg Berghausen | Pharmaceutical Compositions and Solid Forms |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
KR102132405B1 (ko) | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
US20130197016A1 (en) | 2010-10-27 | 2013-08-01 | Mitchell Brigell | Dosing regimes for the treatment of ocular vascular disease |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
JP2014505052A (ja) * | 2011-01-06 | 2014-02-27 | ベータ ファルマ カナダ インコーポレーテッド | 癌の治療および予防用の新規なウレア |
GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
EP2665716B1 (en) | 2011-01-21 | 2017-03-08 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
WO2015064764A1 (ja) * | 2013-11-01 | 2015-05-07 | 宇部興産株式会社 | アリーロイル(オキシ又はアミノ)ペンタフルオロスルファニルベンゼン化合物、薬学的に許容されるその塩、及びそのプロドラッグ |
CN104860885B (zh) * | 2014-02-24 | 2017-11-17 | 中国科学院上海药物研究所 | 萘酰胺类化合物、其制备方法和用途 |
RS64122B1 (sr) | 2014-11-16 | 2023-05-31 | Array Biopharma Inc | Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogensulfata |
JP2018519292A (ja) * | 2015-07-01 | 2018-07-19 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤およびその使用 |
LT3322706T (lt) | 2015-07-16 | 2021-03-10 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-a]piridino junginiai, kaip ret kinazės inhibitoriai |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
WO2017176744A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
HRP20230704T1 (hr) | 2016-05-18 | 2023-10-27 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物 |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
AU2019314302A1 (en) | 2018-07-31 | 2021-01-28 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide |
US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
AU2020413333A1 (en) | 2019-12-27 | 2022-06-16 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
CN115803316A (zh) * | 2020-07-23 | 2023-03-14 | 深圳晶泰科技有限公司 | 吡啶酮类化合物及其制备方法和应用 |
US20230365584A1 (en) | 2020-09-10 | 2023-11-16 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CA2381821A1 (en) * | 1999-08-27 | 2001-03-08 | Boehringer Ingelheim Pharma Kg | Substituted indolinones, their manufacture and their use as medicaments |
CA2400447C (en) | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
US6599926B2 (en) | 2000-06-23 | 2003-07-29 | Bristol-Myers Squibb Company | Heteroaryl-phenyl substituted factor Xa inhibitors |
ES2282299T3 (es) | 2000-10-20 | 2007-10-16 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos. |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
TW200406374A (en) * | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
BR0313871A (pt) * | 2002-08-30 | 2005-07-19 | Eisai Co Ltd | Derivados aromáticos contendo nitrogênio |
TW200418466A (en) * | 2002-11-06 | 2004-10-01 | Smithkline Beecham Corp | Chemical compounds |
BRPI0414011A (pt) | 2003-08-29 | 2006-10-24 | Pfizer | naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos |
CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
GEP20084439B (en) | 2004-01-23 | 2008-07-25 | Amgen Inc | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof |
US7285545B2 (en) | 2004-05-03 | 2007-10-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
GB0421525D0 (en) * | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
-
2005
- 2005-09-12 PE PE2005001058A patent/PE20060664A1/es not_active Application Discontinuation
- 2005-09-13 MY MYPI20054290A patent/MY147640A/en unknown
- 2005-09-13 MY MYPI20092342A patent/MY148246A/en unknown
- 2005-09-13 AR ARP050103817A patent/AR050932A1/es not_active Application Discontinuation
- 2005-09-14 TW TW094131697A patent/TW200626576A/zh unknown
- 2005-09-14 NZ NZ587806A patent/NZ587806A/en not_active IP Right Cessation
- 2005-09-14 NZ NZ587805A patent/NZ587805A/en not_active IP Right Cessation
- 2005-09-14 CA CA2738383A patent/CA2738383A1/en not_active Abandoned
- 2005-09-14 CN CN200910205861A patent/CN101693709A/zh active Pending
- 2005-09-14 KR KR1020107020439A patent/KR20100103890A/ko active IP Right Grant
- 2005-09-14 CA CA2574829A patent/CA2574829C/en not_active Expired - Fee Related
- 2005-09-14 US US11/575,025 patent/US8026247B2/en not_active Expired - Fee Related
- 2005-09-14 BR BRPI0515446-4A patent/BRPI0515446A/pt not_active IP Right Cessation
- 2005-09-14 EP EP05850758A patent/EP1794149A2/en not_active Withdrawn
- 2005-09-14 NZ NZ553094A patent/NZ553094A/en not_active IP Right Cessation
- 2005-09-14 KR KR1020107020440A patent/KR20100111324A/ko not_active Application Discontinuation
- 2005-09-14 MX MX2007003013A patent/MX2007003013A/es active IP Right Grant
- 2005-09-14 GT GT200500260A patent/GT200500260A/es unknown
- 2005-09-14 RU RU2007114124/04A patent/RU2416611C2/ru not_active IP Right Cessation
- 2005-09-14 JP JP2007530802A patent/JP4950889B2/ja not_active Expired - Fee Related
- 2005-09-14 RU RU2010138639/04A patent/RU2448103C2/ru not_active IP Right Cessation
- 2005-09-14 SG SG200906116-9A patent/SG155921A1/en unknown
- 2005-09-14 WO PCT/IB2005/004030 patent/WO2006059234A2/en active Application Filing
- 2005-09-14 AU AU2005310968A patent/AU2005310968C1/en not_active Ceased
- 2005-09-14 KR KR1020077005959A patent/KR20070052309A/ko active IP Right Grant
-
2007
- 2007-03-05 IL IL181720A patent/IL181720A0/en unknown
- 2007-03-14 EC EC2007007324A patent/ECSP077324A/es unknown
- 2007-03-14 TN TNP2007000093A patent/TNSN07093A1/en unknown
- 2007-03-26 MA MA29778A patent/MA28876B1/fr unknown
- 2007-04-13 NO NO20071875A patent/NO20071875L/no not_active Application Discontinuation
-
2009
- 2009-03-18 AU AU2009201090A patent/AU2009201090B2/en not_active Ceased
- 2009-12-30 RU RU2009149216/04A patent/RU2009149216A/ru unknown
-
2011
- 2011-03-08 JP JP2011050331A patent/JP2011148808A/ja active Pending
- 2011-08-17 US US13/211,765 patent/US20110301157A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008513366A5 (ja) | ||
Weisberg et al. | AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL | |
CY1119528T1 (el) | Αναστολεις της δραστηριοτητας της κινασης | |
RU2416611C2 (ru) | Бициклические амиды как ингибиторы киназы | |
CN102573485B (zh) | 三嗪衍生物及其治疗应用 | |
CN106029646B (zh) | 嘧啶‑2,4‑二胺衍生物和含有该衍生物作为活性成分的抗癌药物组合物 | |
PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
MD3755703T2 (ro) | Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului | |
BG108425A (en) | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor | |
EA200970280A1 (ru) | Ингибиторы киназ, полезные для лечения пролиферативных заболеваний | |
EA200970279A1 (ru) | Ингибиторы киназ, полезные для лечения пролиферативных заболеваний | |
JP2013527173A5 (ja) | ||
RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
TW200536851A (en) | Compounds and methods of use | |
Shi et al. | Discovery of N-(2-phenyl-1H-benzo [d] imidazol-5-yl) quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors | |
EA200970700A1 (ru) | Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний | |
NO20073211L (no) | Tibulinbindende anti-cancerstoffer og promedikamenter av disse | |
JP2011520941A5 (ja) | ||
Ji et al. | Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno [2, 3-d] pyrimidines as irreversible epidermal growth factor receptor inhibitors | |
MX2018013235A (es) | Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida. | |
EA201170627A1 (ru) | Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности | |
WO2013036232A3 (en) | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases | |
MY140291A (en) | Sulfoximine-substituted pyrimidines for use as cd and/or vegf inhibitors, the production thereof and their use as drugs | |
EA201001030A1 (ru) | Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла | |
RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета |